Pembrolizumab,Lenvatinib,Sunitinib,Everolimus
Merck,Pfizer,eisai
['sunitinib', 'pembro', 'rcc,(-irccs),(-srcc),(-urcc)', 'lenva']
#clear phase 3 study 4 year follow up also shows persistent benefit of #lenvatinib + #pembro vs #sunitinib in all imdc risk groups in metastatic #rcc mos 49.8mo vs 49.4 hr 0.79 #asco23 
Medical Oncologist, Investigator, Chief, #BladderCancer Section, #GenitourinaryTumors, NCI, NIH #RareTumors #PatientAdvocate, Latina. Views are my own